Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAIN-AF01: adebrelimab + famitinib in PD-L1-high NSCLC with brain metastases
ChiCTR2300079126Phase 2Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Dec 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and famitinib in non-small cell lung cancer (NSCLC), sponsored by Beijing Tiantan Hospital. Primary endpoint: Objective response rate. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
adebrelimabfamitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300079126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300079126.